Literature DB >> 33214164

COVID-19 and IBD drugs: should we change anything at the moment?

Charlie W Lees1,2, Peter M Irving3,4, Laurent Beaugerie5.   

Abstract

Entities:  

Keywords:  azathioprine; covid-19; crohn's disease; inflammatory bowel disease; infliximab

Year:  2020        PMID： 33214164     DOI： 10.1136/gutjnl-2020-323247

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  3 in total

Review 1.  Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview.

Authors:  Amosy Ephreim M'Koma
Journal:  Medicina (Kaunas)       Date:  2022-04-21       Impact factor: 2.948

Review 2.  Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic.

Authors:  Sara El Ouali; David T Rubin; Benjamin L Cohen; Miguel D Regueiro; Florian Rieder
Journal:  Curr Opin Gastroenterol       Date:  2021-07-01       Impact factor: 2.741

3.  Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic.

Authors:  Shahida Din; Daniel Gaya; Jochen Kammermeier; Christopher A Lamb; Jonathan Macdonald; Gordon Moran; Gareth Parkes; Richard Pollok; Shaji Sebastian; Jonathan Segal; Christian Selinger; Philip J Smith; Helen Steed; Ian D Arnott
Journal:  Frontline Gastroenterol       Date:  2021-04-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.